Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Radiochemical separation of no-carrier-added 177Lu as produced via the 176Yb(n,gamma)177Yb-->177Lu process.

Literature DB >> 10972147

Radiochemical separation of no-carrier-added 177Lu as produced via the 176Yb(n,gamma)177Yb-->177Lu process.

N A Lebedev¹, A F Novgorodov, R Misiak, J Brockmann, F Rösch.

Abstract

The 176Yb(n,gamma)177Yb-beta(-)-->177Lu process was investigated to provide no-carrier-added (nca) 177Lu. The radiochemical separation of the 177Lu from the macro-amounts of the ytterbium target based on the cementation process, i.e. the selective extraction of Yb by Na(Hg) amalgam from Cl-/CH3COO- electrolytes, followed by a final cation exchange purification. The cementation separation process provides a decontamination factor of Yb(III) of 10(4), the cation exchange purification adding a decontamination factor of > 10(2). The nca 177Lu is available in radiochemically pure form despite the chemical similarity of the lanthanides with 75 +/- 5% overall separation yield within 4-5 h. It can be used to synthesise nca 177Lu labelled radiotherapeuticals.

Entities: Chemical

Mesh：

Substances：

Year: 2000 PMID： 10972147 DOI： 10.1016/s0969-8043(99)00284-5

Source DB: PubMed Journal: Appl Radiat Isot ISSN： 0969-8043 Impact factor: 1.513

Keyword Cloud
Cited

11 in total

Review 1. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Authors: Ashutosh Dash; Maroor Raghavan Ambikalmajan Pillai; Furn F Knapp
Journal: Nucl Med Mol Imaging Date: 2015-02-17

Review 2. A review of advances in the last decade on targeted cancer therapy using ¹⁷⁷Lu: focusing on ¹⁷⁷Lu produced by the direct neutron activation route.

Authors: Rubel Chakravarty; Sudipta Chakraborty
Journal: Am J Nucl Med Mol Imaging Date: 2021-12-15

3. Stability of ⁴⁷Sc-complexes with acyclic polyamino-polycarboxylate ligands.

Authors: Magdalena Połosak; Agata Piotrowska; Seweryn Krajewski; Aleksander Bilewicz
Journal: J Radioanal Nucl Chem Date: 2012-09-13 Impact factor: 1.371

Review 4. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

Authors: Sandip Basu; Sudipta Chakraborty; Rahul V Parghane; Rohit Ranade; Pradeep Thapa; Ramesh V Asopa; Geeta Sonawane; Swapna Nabar; Hemant Shimpi; Ashok Chandak; K V Vimalnath; Vikas Ostwal; Anant Ramaswamy; Manish Bhandare; Vikram Chaudhari; Shailesh V Shrikhande; Bhawna Sirohi; Ashutosh Dash; Sharmila Banerjee
Journal: Am J Nucl Med Mol Imaging Date: 2020-08-25

Radiochemical separation of no-carrier-added 177Lu as produced via the 176Yb(n,gamma)177Yb-->177Lu process.

Review 1. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Review 2. A review of advances in the last decade on targeted cancer therapy using ¹⁷⁷Lu: focusing on ¹⁷⁷Lu produced by the direct neutron activation route.

3. Stability of ⁴⁷Sc-complexes with acyclic polyamino-polycarboxylate ligands.

Review 4. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

5. Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.

Review 6. The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.

7. (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.

8. Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation.

Review 9. Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases.

10. Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.

Radiochemical separation of no-carrier-added 177Lu as produced via the 176Yb(n,gamma)177Yb-->177Lu process.

Review 1. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Review 2. A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route.

3. Stability of 47Sc-complexes with acyclic polyamino-polycarboxylate ligands.

Review 4. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

5. Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.

Review 6. The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.

7. (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.

8. Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation.

Review 9. Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases.

10. Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.

Review 2. A review of advances in the last decade on targeted cancer therapy using ¹⁷⁷Lu: focusing on ¹⁷⁷Lu produced by the direct neutron activation route.

3. Stability of ⁴⁷Sc-complexes with acyclic polyamino-polycarboxylate ligands.

Review 4. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.